Company news

Impedimed Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

SOZO Pro Achieves Clearance by U.S. FDA

May 4, 2023

Appendix 4C & Quarterly Activities Report - Mar-23 Qtr

April 16, 2023

NCCN Guidelines Now Recommend Bioimpedance Spectroscopy

March 26, 2023

S&P DJI Announces March 2023 Quarterly Rebalance

March 3, 2023

Appendix 4C & Quarterly Activities Report - Dec-22 Qtr

January 29, 2023

New Version of NCCN Guidelines for Breast Cancer

January 29, 2023

ImpediMed Announces Appointment of Managing Director and CEO

November 28, 2022

ImpediMed Announces Management Reorganisation

November 21, 2022

AstraZeneca Further Extends Clinical Trial Contract

November 9, 2022

Appendix 4C & Quarterly Activities Report - Sep-22 Qtr

October 19, 2022

New Corporate Oncology Account with GenesisCare

October 3, 2022

2022 Annual Report & Annual General Meeting Date

August 28, 2022

Appendix 4C & Quarterly Activities Report - Jun-2022 Qtr

July 27, 2022

ImpediMed CEO Announces Departure

July 25, 2022

Lymphoedema Risk Factors Paper Published

July 10, 2022

Appendix 4C & Quarterly Activities Report

April 27, 2022

AstraZeneca extends and increases Renal Contract

March 17, 2022

S&P DJI Announces March 2022 Quarterly Rebalance

March 4, 2022

ImpediMed Announces End Stage Renal Disease Trial Agreement

February 10, 2022

PREVENT Trial Peer-Reviewed and Published

January 31, 2022

Share Purchase Plan Successfully Completed

November 17, 2021

AGM Presentation - November 2021

November 9, 2021

2021 Annual General Meeting - Chairmans Address

November 9, 2021

AstraZeneca extends and increases HF & Renal Contract

November 4, 2021

Share Purchase Plan Offer Booklet

November 3, 2021

ImpediMeds Share Purchase Plan Opens

November 3, 2021

Capital Raising Presentation

October 26, 2021

ImpediMed Completes A$35 Million Institutional Placement

October 26, 2021

PREVENT Trial Successful, Statistically Significant Results

October 19, 2021

New Corporate Oncology Account with Icon Group

September 29, 2021

SOZO Heart Failure Program Initiated at AdvocateAuroraHealth

September 26, 2021

HFSA Abstracts Demonstrate Utility of SOZO for HF Patients

September 12, 2021

Receipt of $1.8 Million R&D Tax Incentive Refund

August 24, 2021

FDA Grants Breakthrough Device Designation for Renal Failure

August 22, 2021

Official Release of SOZO Version 4.0 Software

May 24, 2021

ACC Abstract Demonstrates Potential of SOZO in Heart Failure

May 4, 2021

Appendix 4C - Quarter ended 31 March 2021

April 27, 2021

FDA Clearance for SOZO Heart Failure Index

April 21, 2021

SOZO Clinical Utility in Heart Failure Published

April 7, 2021

Option Exercise and Preliminary Q3 FY21 Cashflow Results

April 6, 2021

ImpediMed Achieves Milestone 200,000 SOZO Patient Tests

March 3, 2021

Appendix 4D - Half-Year Results Ended 31 December 2020

February 21, 2021

American College of Cardiology Accepts SOZO HF Abstract

February 11, 2021

Appendix 4C - Quarter ended 31 December 2020

January 27, 2021

PREVENT Trial Finishes, Final Patient Completes Follow-up

January 11, 2021

Option Exercise and Preliminary Quarterly Cash Flow Results

January 6, 2021

Meta-Analysis-BIS L-Dex Statistically Significant Reduction

November 29, 2020

ImpediMed Secures First Commercial Heart Failure Sales

November 17, 2020

AstraZeneca Selects SOZO for Second Large Renal Trial

November 9, 2020

Landmark Radiation Manuscript Supports L-Dex Use

October 28, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 7 calls. Every call is listed under its year.

Decks

The 5 newest of 71 decks. Every deck is listed under its year.